Glucolipotoxicity and beta cells in type 2 diabetes mellitus: Target for durable therapy?

Diabetes Research and Clinical Practice

Volumn 93, Issue SUPPL. 1, 2011, Pages

  Van Raalte, Daniel H ^a   Diamant, Michaela ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Beta cell dysfunction; Beta cell mass; Diabetes treatment; Glucolipotoxicity; Type 2 diabetes mellitus

Indexed keywords

CALCIUM ION; CHLORPROPAMIDE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; FATTY ACID; GLIBENCLAMIDE; GLIMEPIRIDE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INCRETIN; INSULIN GLARGINE; LIRAGLUTIDE; METFORMIN; PIOGLITAZONE; PLACEBO; RAMIPRIL; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA DERIVATIVE; VILDAGLIPTIN;

APOPTOSIS; ARTICLE; CELL MEMBRANE DEPOLARIZATION; CELL PROTECTION; COMBINATION CHEMOTHERAPY; DISEASE COURSE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; ENDOPLASMIC RETICULUM STRESS; GLUCOLIPOTOXICITY; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; INFLAMMATION; INSULIN RELEASE; INSULIN SENSITIVITY; INSULIN TREATMENT; INTENSIVE CARE; ISLET CELL INFLAMMATION; LIPOTOXICITY; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION;

ANIMALS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN-SECRETING CELLS; METFORMIN; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 84860390432     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/S0168-8227(11)70012-2     Document Type: Article

References (82)

1. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998, 352(9131):854-865.
2. Turner RC, Cull CA, Frighi V, Holman RR glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999, 281(21):2005-2012.
3. Heine RJ, Diamant M, Mbanya JC, Nathan DM Management of hyperglycaemia in type 2 diabetes: the end of recurrent failure?. BMJ 2006, 333(7580):1200-1204.
4. Kahn SE The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 2003, 46(1):3-19.
5. de Koning EJ, Bonner-Weir S, Rabelink TJ Preservation of beta-cell function by targeting beta-cell mass. Trends Pharmacol Sei 2008, 29(4):218-227.
6. Bonner-Weir S, O'Brien TD Islets in type 2 diabetes: in honor of Dr. Robert C. Turner. Diabetes 2008, 57(11):2899-2904.
7. Defronzo RA, Triplitt C, Qu Y, Lewis MS, Maggs D, Glass LC Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin. Diabetes Care 2010, 33(5):951-957.
8. Salehi M, Aulinger BA, DAlessio DA Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretins. Endocr Rev 2008, 29(3):367-379.
9. Butler AE, Janson J, Bonner-Weir S, Ritzel R, Rizza RA, Butler PC Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003, 52(1):102-110.
10. Ritzel RA, Butler AE, Rizza RA, Veldhuis JD, Butler PC Relationship between beta-cell mass and fasting blood glucose concentration in humans. Diabetes Care 2006, 29(3):717-718.
11. Poitout V, Robertson RP Glucolipotoxicity: fuel excess and beta-cell dysfunction. Endocr Rev 2008, 29(3):351-366.
12. Eizirik DL, Cardozo AK, Cnop M The role for endoplasmic reticulum stress in diabetes mellitus. Endocr Rev 2008, 29(1):42-61.
13. Marchetti P, Bugliani M, Lupi R, Marselli L, Masini M, Boggi U, et al. The endoplasmic reticulum in pancreatic beta cells of type 2 diabetes patients. Diabetologia 2007, 50(12):2486-2494.
14. Li N, Frigerio F, Maechler P The sensitivity of pancreatic beta-cells to mitochondrial injuries triggered by lipotoxicity and oxidative stress. Biochem Soc Trans 2008, 36(Pt 5):930-934.
15. Li N, Brun T, Cnop M, Cunha DA, Eizirik DL, Maechler P Transient oxidative stress damages mitochondrial machinery inducing persistent beta-cell dysfunction. J Biol Chem 2009, 284(35):23602-23612.
16. Wajchenberg BL Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007, 28(2):187-218.
17. Prentki M, Nolan CJ Islet beta cell failure in type 2 diabetes. J Clin Invest 2006, 116(7):1802-1812.
18. Maedler K, Sergeev P, Ris F, Oberholzer J, Joller-Jemelka HI, Spinas GA, et al. Glucose-induced beta cell production of IL-lbeta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 2002, 110(6):851-860.
19. Welsh N, Cnop M, Kharroubi I, Bugliani M, Lupi R, Marchetti P, et al. Is there a role for locally produced interleukin-1 in the deleterious effects of high glucose or the type 2 diabetes milieu to human pancreatic islets?. Diabetes 2005, 54(11):3238-3244.
20. Cnop M, Welsh N, Jonas JC, Jorns A, Lenzen S, Eizirik DL Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes 2005, 54(Suppl 2):S97-107.
21. Paolisso G, Tataranni PA, Foley JE, Bogardus C, Howard BV, Ravussin E A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM. Diabetologia 1995, 38(10):1213-1217.
22. Teusink B, Voshol PJ, Dahlmans VE, Rensen PC, Pijl H, Romijn JA, et al. Contribution of fatty acids released from lipolysis of plasma triglycerides to total plasma fatty acid flux and tissue-specific fatty acid uptake. Diabetes 2003, 52(3):614-620.
23. Poitout V, Robertson RP Minireview: Secondary beta-cell failure in type 2 diabetes - a convergence of glucotoxicity and lipotoxicity. Endocrinology 2002, 143(2):339-342.
24. Lupi R, Dotta F, Marselli L, Del GS, Masini M, Santangelo C, et al. Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: evidence that beta-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated. Diabetes 2002, 51(5):1437-1442.
25. Oprescu AI, Bikopoulos G, Naassan A, Allister EM, Tang C, Park E, et al. Free fatty acid-induced reduction in glucose-stimulated insulin secretion: evidence for a role of oxidative stress in vitro and in vivo. Diabetes 2007, 56(12):2927-2937.
26. Poitout V Glucolipotoxicity of the pancreatic beta-cell: myth or reality?. Biochem Soc Trans 2008, 36(Pt 5):901-904.
27. Cnop M, Igoillo-Esteve M, Cunha DA, Ladriere L, Eizirik DL An update on lipotoxic endoplasmic reticulum stress in pancreatic beta-cells. Biochem Soc Trans 2008, 36(Pt 5):909-915.
28. Cnop M Fatty acids and glucolipotoxicity in the pathogenesis of Type 2 diabetes. Biochem Soc Trans 2008, 36(Pt 3):348-352.
29. Carpentier A, Mittelman SD, Lamarche B, Bergman RN, Giacca A, Lewis GF Acute enhancement of insulin secretion by FFA in humans is lost with prolonged FFA elevation. Am J Physiol 1999, 276(6 Pt l):E1055-E1066.
30. Paolisso G, Gambardella A, Amato L, Tortoriello R, Amore DA, Varricchio M, et al. Opposite effects of short- and long-term fatty acid infusion on insulin secretion in healthy subjects. Diabetologia 1995, 38(11):1295-1299.
31. Amery CM, Round RA, Smith JM, Nattrass M Elevation of plasma fatty acids by ten-hour intralipid infusion has no effect on basal or glucose-stimulated insulin secretion in normal man. Metabolism 2000, 49(4):441-450.
32. Balent B, Goswami G, Goodloe G, Rogatsky E, Rauta O, Nezami R, et al. Acute elevation of NEFA causes hyperinsulinemia without effect on insulin secretion rate in healthy human subjects. Ann N Y Acad Sei 2002, 967:535-543.
33. Boden G, Chen X, Rosner J, Barton M Effects of a 48-h fat infusion on insulin secretion and glucose utilization. Diabetes 1995, 44(10):1239-1242.
34. Magnan C, Cruciani C, Clement L, Adnot P, Vincent M, Kergoat M, et al. Glucose-induced insulin hypersecretion in lipid-infused healthy subjects is associated with a decrease in plasma norepinephrine concentration and urinary excretion. J Clin Endocrinol Metab 2001, 86(10):4901-4907.
35. Leung N, Sakaue T, Carpentier A, Uffelman K, Giacca A, Lewis GF Prolonged increase of plasma non-esterified fatty acids fully abolishes the stimulatory effect of 24 hours of moderate hyperglycaemia on insulin sensitivity and pancreatic beta-cell function in obese men. Diabetologia 2004, 47(2):204-213.
36. Carpentier A, Mittelman SD, Bergman RN, Giacca A, Lewis GF Prolonged elevation of plasma free fatty acids impairs pancreatic beta-cell function in obese nondiabetic humans but not in individuals with type 2 diabetes. Diabetes 2000, 49(3):399-408.
37. Boden G, Chen X Effects of fatty acids and ketone bodies on basal insulin secretion in type 2 diabetes. Diabetes 1999, 48(3):577-583.
38. Kashyap S, Belfort R, Gastaldelli A, Pratipanawatr T, Berria R, Pratipanawatr W, et al. A sustained increase in plasma free fatty acids impairs insulin secretion in nondiabetic subjects genetically predisposed to develop type 2 diabetes. Diabetes 2003, 52(10):2461-2474.
39. Cusi K, Kashyap S, Gastaldelli A, Bajaj M, Cersosimo E Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes. Am J Physiol Endocrinol Metab 2007, 292(6):E1775-E1781.
40. Prentki M, Corkey BE Are the beta-cell signaling molecules malonyl-CoA and cystolic long-chain acyl-CoA implicated in multiple tissue defects of obesity and NIDDM?. Diabetes 1996, 45(3):273-283.
41. Li Y, Xu W, Liao Z, Yao B, Chen X, Huang Z, et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. Diabetes Care 2004, 27(11):2597-2602.
42. Ryan EA, Imes S, Wallace C Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care 2004, 27(5):1028-1032.
43. Weng J, Li Y, Xu W, Shi L, Zhang Q, Zhu D, et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 2008, 371(9626):1753-1760.
44. Bunck MC, Mari A, Corner A, Eliasson B, Shaginian RM, Wu Y, et al. One-year exenatide treatment improves beta cell response in metformin treated patients with type 2 diabetes which is sustained after 5 weeks of discontinuation of treatment. Diabetologia 2010, 52:S7.
45. Marchetti P, Del GS, Marselli L, Lupi R, Masini M, Pollera M, et al. Pancreatic islets from type 2 diabetic patients have functional defects and increased apoptosis that are ameliorated by metformin. J Clin Endocrinol Metab 2004, 89(11):5535-5541.
46. Lupi R, Del GS, Tellini C, Giannarelli R, Coppelli A, Lorenzetti M, et al. The biguanide compound metformin prevents desensitization of human pancreatic islets induced by high glucose. Eur J Pharmacol 1999, 364(2-3):205-209.
47. Lupi R, Del GS, Fierabracci V, Marselli L, Novelli M, Patane G, et al. Lipotoxicity in human pancreatic islets and the protective effect of metformin. Diabetes 2002, 51(Suppl l):S134-S137.
48. Patane G, Piro S, Rabuazzo AM, Anello M, Vigneri R, Purrello F Metformin restores insulin secretion altered by chronic exposure to free fatty acids or high glucose: a direct metformin effect on pancreatic beta-cells. Diabetes 2000, 49(5):735-740.
49. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006, 355(23):2427-2443.
50. Del Guerra S, Marselli L, Lupi R, Boggi U, Mosca F, Benzi L, et al. Effects of prolonged in vitro exposure to sulphonylureas on the function and survival of human islets. J Diabetes Complications 2005, 19(1):60-64.
51. Efanova IB, Zaitsev SV, Zhivotovsky B, Kohler M, Efendic S, Orrenius S, et al. Glucose and tolbutamide induce apoptosis in pancreatic beta-cells. A process dependent on intracellular Ca2+ concentration. J Biol Chem 1998, 273(50):33501-33507.
52. Maedler K, Carr RD, Bosco D, Zuellig RA, Berney T, Donath MY Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab 2005, 90(1):501-506.
53. Remedi MS, Nichols CG Chronic antidiabetic sulfonylureas in vivo: reversible effects on mouse pancreatic beta-cells. PLoS Med 2008, 5(10):e206.
54. Del Guerra S, Grupillo M, Masini M, Lupi R, Bugliani M, Torri S, et al. Gliclazide protects human islet beta-cells from apoptosis induced by intermittent high glucose. Diabetes Metab Res Rev 2007, 23(3):234-238.
55. Sawada F, Inoguchi T, Tsubouchi H, Sasaki S, Fujii M, Maeda Y, et al. Differential effect of sulfonylureas on production of reactive oxygen species and apoptosis in cultured pancreatic beta-cell line, MIN6. Metabolism 2008, 57(8):1038-1045.
56. Campbell IW, Mariz S Beta-cell preservation with thiazolidinediones. Diabetes Res Clin Pract 2007, 76(2):163-176.
57. Abaraviciene SM, Lundquist I, Salehi A Rosiglitazone counteracts palmitate-induced beta-cell dysfunction by suppression of MAP kinase, inducible nitric oxide synthase and caspase 3 activities. Cell Mol Life Sei 2008, 65(14):2256-2265.
58. Diani AR, Sawada G, Wyse B, Murray FT, Khan M Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of type 2 diabetes. Am J Physiol Endocrinol Metab 2004, 286(1):E116-E122.
59. Saitoh Y, Chun-ping C, Noma K, Ueno H, Mizuta M, Nakazato M Pioglitazone attenuates fatty acid-induced oxidative stress and apoptosis in pancreatic beta-cells. Diabetes Obes Metab 2008, 10(7):564-573.
60. Akiyama M, Hatanaka M, Ohta Y, Ueda K, Yanai A, Uehara Y, et al. Increased insulin demand promotes while pioglitazone prevents pancreatic beta cell apoptosis in Wfsl knockout mice. Diabetologia 2009, 52(4):653-663.
61. Finegood DT, McArthur MD, Kojwang D, Thomas MJ, Topp BG, Leonard T, et al. Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. Diabetes 2001, 50(5):1021-1029.
62. Mazzone T, Meyer PM, Feinstein SB, Davidson MH, Kondos GT, DAgostino RB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006, 296(21):2572-2581.
63. Vilsboll T The effects of glucagon-like peptide-1 on the beta cell. Diabetes Obes Metab 2009, 11(Suppl):311-318.
64. Buteau J, El-Assaad W, Rhodes CJ, Rosenberg L, Joly E, Prentki M Glucagon-like peptide-1 prevents beta cell glucolipotoxicity. Diabetologia 2004, 47(5):806-815.
65. Cunha DA, Ladriere L, Ortis F, Igoillo-Esteve M, Gurzov EN, Lupi R, et al. Glucagon-like peptide-1 agonists protect pancreatic beta-cells from lipotoxic endoplasmic reticulum stress through upregulation of BiP and JunB. Diabetes 2009, 58(12):2851-2862.
66. Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 2003, 278(1):471-478.
67. Rolin B, Larsen MO, Gotfredsen CF, Deacon CF, Carr RD, Wilken M, et al. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. Am J Physiol Endocrinol Metab 2002, 283(4):E745-E752.
68. Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004, 27(11):2628-2635.
69. Defronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005, 28(5):1092-1100.
70. Fineman MS, Bicsak TA, Shen LZ, Taylor K, Gaines E, Varns A, et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 2003, 26(8):2370-2377.
71. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009, 374(9683):39-47.
72. Vilsboll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Courreges JP, et al. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007, 30(6):1608-1610.
73. Mari A, Nielsen LL, Nanayakkara N, Defronzo RA, Ferrannini E, Halseth A Mathematical modeling shows exenatide improved beta-cell function in patients with type 2 diabetes treated with metformin or metformin and a sulfonylurea. Horm Metab Res 2006, 38(12):838-844.
74. Mari A, Degn K, Brock B, Rungby J, Ferrannini E, Schmitz O Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditions. Diabetes Care 2007, 30(8):2032-2033.
75. Bunck MC, Diamant M, Corner A, Eliasson B, Malloy JL, Shaginian RM, et al. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 2009, 32(5):762-768.
76. Vilsboll T, Brock B, Perrild H, Levin K, Lervang HH, Kolendorf K, et al. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. Diabet Med 2008, 25(2):152-156.
77. Duttaroy A, Voelker F, Merriam K, Zhang X, Ren X, Burkey B The DPP-4 inhibitor vildagliptin increases pancreatic beta cell neogenesis and decreases apoptosis. Diabetes 2010, 54(Suppl 1):A141.
78. Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007, 9(5):733-745.
79. Pratley RE, Schweizer A, Rosenstock J, Foley JE, Banerji MA, Pi-Sunyer FX, et al. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naive patients: analysis of pooled vildagliptin monotherapy database. Diabetes Obes Metab 2008, 10(10):931-938.
80. Mari A, Sallas WM, He YL, Watson C, Ligueros-Saylan M, Dunning BE, et al. Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes. J Clin Endocrinol Metab 2005, 90(8):4888-4894.
81. Nonaka K, Kakikawa T, Sato A, Okuyama K, Fujimoto G, Kato N, et al. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2008, 79(2):291-298.
82. Defronzo RA Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009, 58(4):773-795.